4.2 Article

The Role of the Androgen Receptor in the Development and Progression of Bladder Cancer

期刊

JAPANESE JOURNAL OF CLINICAL ONCOLOGY
卷 42, 期 7, 页码 569-577

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jjco/hys072

关键词

androgens; androgen receptor; bladder cancer; carcinogenesis; progression

类别

资金

  1. Department of Defense [W81XWH-09-1-0305]

向作者/读者索取更多资源

Men are at a higher risk of developing bladder cancer than women. Since bladder cancer cell lines and tissues were found to express the androgen receptor, efforts have been made to inspect whether androgen-mediated androgen receptor signals are implicated in bladder carcinogenesis as well as cancer progression. Mounting evidence supports the view that bladder cancer is a member of the endocrine-related tumors and may clearly explain the gender-specific difference in the incidence. However, the underlying mechanisms of how androgen receptor signals regulate bladder cancer growth are still far from fully characterized. Moreover, it remains controversial whether the androgen receptor pathway always plays a dominant role in bladder cancer progression. In this review, we summarize the available data on the involvement of androgen receptor signaling in bladder cancer. In particular, current evidence demonstrating the stimulatory effects of androgens on tumor progression or, more convincingly, tumorigenesis via the androgen receptor pathway may offer great potential for androgen deprivation as a therapeutic or chemopreventive option in patients with bladder cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pathology

Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features

Natalie M. Rizzo, Lynette M. Sholl, Muhammad T. Idrees, John C. Cheville, Sounak Gupta, Kristine M. Cornejo, Hiroshi Miyamoto, Michelle S. Hirsch, Katrina Collins, Andres M. Acosta

Summary: This study compared the genomic landscape of aggressive and nonaggressive testicular Leydig cell tumors (LCTs) and found that aggressive LCTs are characterized by FH inactivation and multiple copy number changes, while nonaggressive LCTs do not exhibit these characteristics.

MODERN PATHOLOGY (2021)

Article Pathology

Clinical significance of perineural invasion by prostate cancer on magnetic resonance imaging-targeted biopsy

Nivedita Suresh, Yuki Teramoto, Takuro Goto, Ying Wang, Hiroshi Miyamoto

Summary: This study evaluated the perineural invasion of prostate cancer detected on magnetic resonance imaging-targeted biopsy and found its association with pathological features and prognosis.

HUMAN PATHOLOGY (2022)

Article Pathology

Secondary malignancy after urologic reconstruction procedures: a multi-institutional case series

Chelsea Cornell, Francesca Khani, Adeboye O. Osunkoya, Andres Matoso, Hiroshi Miyamoto, Jennifer B. Gordetsky, Safia N. Salaria, Giovanna A. Giannico

Summary: This study evaluates the clinicopathological features of secondary tumors arising after urologic reconstruction procedures. The study includes 11 cases with an average age of 51.7 years and a male-to-female ratio of 8:3. The tumors are mostly adenocarcinomas, presenting late and behaving aggressively.

HUMAN PATHOLOGY (2022)

Letter Pathology

Pulse granuloma in the distal ureter, a malignancy mimicker

Sarah K. Findeis, Hani Rashid, Hiroshi Miyamoto, Yansheng Hao

PATHOLOGY INTERNATIONAL (2022)

Article Oncology

Radical prostatectomy findings and oncologic outcomes in patients with prostate cancer detected on systematic sextant biopsy only, MRI-targeted biopsy only, or both

Nivedita Suresh, Yuki Teramoto, Ying Wang, Hiroshi Miyamoto

Summary: This study compared prostate cancer detection on T-Bx and S-Bx and found that detection on T-Bx was associated with larger tumor volume and worse prognosis. However, simultaneous tumor detection on S-Bx in patients with prostate cancer on T-Bx did not have a significant clinicopathologic impact.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

Article Cell Biology

Prostatic malakoplakia: clinicopathological assessment of a multi-institutional series of 49 patients

Andres M. Acosta, Ankur R. Sangoi, Fiona Maclean, Kiril Trpkov, Adeboye O. Osunkoya, Katrina Collins, Hiroshi Miyamoto, Michelle S. Hirsch, Emily Chan, Maria Tretiakova, Sambit K. Mohanty, Seema Kaushal, Kristine M. Cornejo, Manju Aron, Gabriela Quiroga-Garza, Kanika Arora, Jane K. Nguyen, Sean R. Williamson, Jonathan Epstein, Andres Matoso

Summary: Prostatic malakoplakia (MP) is a rare disease with unclear clinicopathological features. In this study, the authors analyzed the clinicopathological characteristics of 49 patients with prostatic MP and found that most patients manifested MP clinically, and some patients had concurrent prostate cancer.

HISTOPATHOLOGY (2022)

Article Pathology

Clinical Significance of Perineural Invasion by Prostate Cancer Detected on Needle Core Biopsy Unilateral vs Bilateral Involvement

Yuki Teramoto, Numbereye Numbere, Ying Wang, Hiroshi Miyamoto

Summary: The laterality of perineural invasion (PNI) in prostate cancer has a significant impact on clinical outcomes. Patients with bilateral PNI have a higher risk of disease progression after radical prostatectomy (RP) compared to those with unilateral PNI.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2023)

Review Oncology

Recent advances in the understanding of urothelial tumorigenesis

Masato Yasui, Liam Cui, Hiroshi Miyamoto

Summary: Patients with non-muscle-invasive bladder tumor often experience recurrence even after surgery, and muscle-invasive disease is often fatal. It is crucial to understand the molecular mechanisms responsible for bladder tumor progression and tumorigenesis.

EXPERT REVIEW OF ANTICANCER THERAPY (2023)

Article Pathology

Comedonecrosis within conventional prostatic adenocarcinoma vs. intraductal carcinoma of the prostate: their clinical significance is not comparable*

Ying Wang, Yuki Teramoto, Hiroshi Miyamoto

Summary: It is controversial whether Gleason grade should be assigned to intraductal carcinoma of the prostate (IDC-P) and if the prognostic value of comedonecrosis associated with IDC-P is equivalent to that in conventional/invasive prostatic adenocarcinoma (CPA) as a Gleason grade 5 pattern. This study evaluated radical prostatectomy findings and postoperative outcomes in 287 patients with CPA exhibiting any Gleason pattern 5. The presence of necrosis only in IDC-P was found to be associated with significantly worse oncologic outcomes, compared with necrosis only in CPA, suggesting that IDC-P necrosis should not be simply considered as a grade 5 pattern.

HUMAN PATHOLOGY (2023)

Article Oncology

The impact of routine frozen section analysis during nephroureterectomy or segmental ureterectomy for urothelial carcinoma on final surgical margin status and long-term oncologic outcome

Wilrama Lima, Ying Wang, Hiroshi Miyamoto

Summary: This study evaluated the clinical significance of intraoperative frozen section analysis (FSA) in patients with upper urinary tract cancer. The results showed that FSA can significantly reduce the risk of positive surgical margins in patients with ureteral tumors, but routine FSA for upper urinary tract cancer did not improve long-term oncologic outcomes significantly.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2023)

Article Urology & Nephrology

Risk Stratification by Quantification of Perineural Cancer Invasion on Prostate Needle Core Biopsy: Should It Be Counted?

Yuki Teramoto, Ying Wang, Hiroshi Miyamoto

Summary: Quantification of perineural invasion on prostate biopsy showed significance as an independent predictor of prognosis, with multifocal perineural invasion and >1 perineural invasion per 10-mm tumor associated with worse outcomes after radical prostatectomy. Additionally, assigning points for multifocal perineural invasion improved the accuracy of predicting 5-year recurrence-free survival.

JOURNAL OF UROLOGY (2023)

Review Chemistry, Medicinal

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy

Tomoyuki Tatenuma, Hiroshi Miyamoto

Summary: Androgen deprivation therapy is the main treatment for advanced prostate cancer, and relugolix has been developed as an oral alternative. Previous studies have shown comparable efficacy between relugolix and other gonadotropin-releasing hormone antagonists or agonists. This review summarizes the design, development, and therapeutic application of relugolix and discusses its potential as a promising oral alternative to injectable therapy.

DRUG DESIGN DEVELOPMENT AND THERAPY (2023)

暂无数据